Reunion Neuroscience Inc. (NASDAQ: REUN | TSX: REUN), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today announced it will be participating in the following investor conferences in December 2022.
Stifel Canada’s The Future of Healthcare Conference
Date: Wednesday, December 7, 2022
Time: 2:00 p.m. ET
Format: Presentation
Webcast: bit.ly/3AT6tFb
Canaccord Genuity Symposium on New Paradigms and Treatment Approaches in Mental Health
Date: Tuesday, December 13, 2022
Time: 10:00 a.m. ET
Format: Virtual panel ‘Opportunities/Challenges in Changing the Status Quo on Mental Health Therapeutics’
Registration: Please contact your Canaccord Genuity representative to register
KCSA Mental Health Conference
Date: Thursday, December 15, 2022
Time: 10:00 a.m. ET
Format: Virtual presentation
Webcast: https://bit.ly/3Ub0iE3
Recordings of the webcast presentations will be available on the Events and Presentations section of Reunion’s investor relations website following the events.
The Reunion management team will also participate in one-on-one investor meetings during the conferences. For institutional investors to schedule a meeting, please contact reunion@kcsa.com.
About Reunion Neuroscience Inc
Reunion (formerly, Field Trip Health Ltd.) is committed to developing innovative therapeutic solutions for mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depression and other mental health conditions. The U.S. Patent and Trademark Office has granted the Company a patent for the claims related to RE104, granting it exclusive rights to the composition of matter, use and manufacturing of a family of hemi-ester compounds of hydroxytryptamines, including RE104. The patent will provide protection until 2041. Reunion is also developing the RE200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psychoactivity for potential use in more chronic treatment paradigms and indications.